We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Targeted Breast Radiation Device Designed to Control Cancer

By HospiMedica International staff writers
Posted on 12 Aug 2010
A new study of breast cancer patients demonstrated that after nearly two years, the radiation given with a strut-adjusted volume implant (SAVI) controls the rate of cancer and may reduce the complications seen with alternate types of brachytherapy. More...
This study also demonstrates the accuracy and flexibility of the device to maximize the dose to the target tissue and minimize the exposure of healthy surrounding tissue and organs.

The study was conducted at Moores University of California, San Diego (UCSD) Cancer Center (USA) and the Arizona Oncology Services (Phoenix, USA). "This is the first paper that documents the patients' status after almost two years,” said Catheryn Yashar, M.D., associate professor of radiation oncology at the UCSD School of Medicine and chief of breast and gynecological radiation services at the Moores UCSD Cancer Center (USA). "After almost two years, the patients showed that the treatment was well-tolerated without experiencing significant side effects. To date, the control rate of cancer is also very promising.”

SAVI, which consists of comfortable, flexible catheters through which radiation is given, provides personalized radiation therapy and minimizes exposure to healthy tissue after a woman who has undergone a lumpectomy to remove a cancerous tumor. Radiation specialists sometimes choose to give women internal radiation a method called brachytherapy with the goal of giving concentrated doses of radiation to regions of concern while avoiding healthy tissue.

The study's findings, reported online June 18, 2010, in the International Journal of Radiation Oncology, Biology and Physics, revealed the results of 102 patients treated at a median follow-up time of 21 months. The researchers found that the SAVI appears to allow safely an increase in eligibility for patients to receive accelerated partial breast irradiation (APBI) over balloon brachytherapy or three-dimensional conformal radiation.

"This treatment allows us to provide internal radiation to the area without damaging the healthy tissue around the site, and minimizes radiation to a duration of only five days,” explained Dr. Yashar. "The traditional whole breast treatment usually takes approximately six weeks.”

The SAVI device was developed by Cianna Medical (Aliso Viejo, CA, USA).

Related Links:
Moores UCSD Cancer Center
Arizona Oncology Services
Cianna Medical


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.